Literature DB >> 25441012

Care of patients undergoing vascular surgery at safety net public hospitals is associated with higher cost but similar mortality to nonsafety net hospitals.

Mohammad H Eslami1, Denis Rybin2, Gheorghe Doros2, Alik Farber3.   

Abstract

OBJECTIVE: This study compared in-hospital mortality and resource utilization among vascular surgical patients at safety net public hospitals (SNPHs) with those at nonsafety net public hospitals (nSNPHs).
METHODS: The National Inpatient Sample (2003-2011) was queried to identify surgical patients with peripheral arterial disease (PAD), carotid stenosis, or nonruptured abdominal aorta aneurysm based on International Classification of Diseases, Ninth Revision, Clinical Modification diagnostic and procedure codes. The cohort was then divided into SNPH and nSNPH groups according to the definition of SNPH used by the National Association of Public Hospitals. Clinical characteristics, length of stay, in-hospital mortality, and hospital charges were compared between groups. Advanced PAD was defined as that associated with rest pain or tissue loss. Statistical methods included bivariate χ(2) tests for categoric variables, t-tests for continuous variables, and multivariable linear and logistic regression to adjust for confounding variables (in-hospital mortality).
RESULTS: We identified 306,438 patients operated on for PAD, carotid stenosis, and abdominal aortic aneurysm. Patients at SNPHs were younger, the percentage of female and minority patients was higher, and patients had a higher Elixhauser comorbidity index (P < .001). Nonelective admissions were more common among SNPH patients who presented with more advanced PAD (P > .05) and symptomatic carotid stenosis (P < .05). Patients at SNPHs had a significantly longer length of stay, higher hospital charges, and higher in-hospital mortality (P < .05 for all variables). Crude odds of mortality at SNPHs were 1.28 higher than at nSNPHs (95% confidence interval, 1.13-1.46; P < .001), but adjusted analyses revealed no statistically significant difference between the odds of in-hospital mortality at both hospital groups.
CONCLUSIONS: Patients undergoing vascular surgery at SNPHs, despite being younger, had higher comorbidities, presented more urgently with more advanced disease, and incurred higher costs than the SNPH cohort despite similar adjusted odds of in-hospital mortality. Delayed presentation and higher comorbidities are most likely related to poor access to routine and preventive health care for the SNPH patients.
Copyright © 2014 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25441012     DOI: 10.1016/j.jvs.2014.08.055

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  5 in total

1.  Utilization and Outcomes of Inpatient Urological Care at Safety Net Hospitals.

Authors:  Lindsey A Herrel; Zaojun Ye; David C Miller
Journal:  J Urol       Date:  2015-04-30       Impact factor: 7.450

2.  Management of glioblastoma at safety-net hospitals.

Authors:  Michael G Brandel; Robert C Rennert; Christian Lopez Ramos; David R Santiago-Dieppa; Jeffrey A Steinberg; Reith R Sarkar; Arvin R Wali; J Scott Pannell; James D Murphy; Alexander A Khalessi
Journal:  J Neurooncol       Date:  2018-04-24       Impact factor: 4.130

3.  A cohort study of a general surgery electronic consultation system: safety implications and impact on surgical yield.

Authors:  Jesus G Ulloa; Marika D Russell; Alice Hm Chen; Delphine S Tuot
Journal:  BMC Health Serv Res       Date:  2017-06-23       Impact factor: 2.655

4.  The impact of hospital safety-net status on inpatient outcomes for brain tumor craniotomy: a 10-year nationwide analysis.

Authors:  Oliver Y Tang; Krissia M Rivera Perla; Rachel K Lim; Robert J Weil; Steven A Toms
Journal:  Neurooncol Adv       Date:  2020-12-01

5.  Outcomes and Costs of Managing Appendicitis at Safety-Net Hospitals.

Authors:  Roy P Won; Scott Friedlander; Steven L Lee
Journal:  JAMA Surg       Date:  2017-11-01       Impact factor: 14.766

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.